BioSpace News Archive

Business

Kronos Bio Snags $105 Million to Support Development of its Small Molecule Microarray Platform

Since its launch, Kronos has demonstrated SMM’s potential to identify compounds that bind to target proteins directly or interfere at nanomolar potency with protein activity.

July 18, 2019
·
2 min read
·
Alex Keown
Business

Bayer, Bristol-Myers Squibb and Ono Pharma Team on Colorectal Cancer

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Co. have teamed up to study the most common type of metastatic colorectal cancer (mCRC).

July 18, 2019
·
2 min read
·
Mark Terry
Deals

Genmab Raises $506 Million in IPO

Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB.

July 18, 2019
·
2 min read
·
Mark Terry
Business

Boehringer Ingelheim Gambles $2.62 Billion on Two Fibrotic Disease Deals

Bridge Biotherapeutics licensed out its BB-877 to Boehringer Ingelheim for a total deal of about $1.75 billion. This is the second large deal for fibrotic diseases Boehringer Ingelheim inked since the beginning of the month.

July 18, 2019
·
3 min read
·
Mark Terry
Business

Novartis Close to Settling Kickback Lawsuit

Novartis saw a strong boost in sales during the second quarter, driven by Cosentyx and Entresto, as well as a 9% growth in oncology sales, the company announced this morning.

July 18, 2019
·
3 min read
·
Alex Keown
Business

Mallinckrodt and Silence Therapeutics Forge RNAi Deal Worth up to $2 Billion

The companies will develop therapies that target the complement cascade, a group of proteins known to play a role in autoimmune diseases.

July 18, 2019
·
3 min read
·
Alex Keown
Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt

In May, the company sold off assets worth $5.7 billion and now, the company is looking to sell more.

July 18, 2019
·
2 min read
·
Alex Keown
Deals

Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019

Assertio Therapeutics, Inc. announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019, after the close of markets.

July 18, 2019
·
1 min read
Drug Development

MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi

MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.

July 18, 2019
·
7 min read
Business

Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States

Research Triangle Park Facility to Manufacture Precision’s Pipeline of Off-the-Shelf CAR T Product Candidates to Support Clinical Trials

July 18, 2019
·
5 min read